COR Stock Price Prediction

Cencora Inc

COR

Cencora Inc

278.470

+1.060(+0.380%)

COR Price Prediction Next Week

Analysis and Insights

To predict the stock price of Corcept Therapeutics (CORT) for the next trading week, we analyze both technical indicators and recent news sentiment.

Technical Analysis:

RSI (14): 48.95 (neutral, not oversold or overbought)
MACD: -1.41 (bearish signal line crossover)
Fibonacci Levels: Pivot at 56.43, resistance at 59.02, and support at 53.85

News Sentiment:

Insider Activity: Significant insider selling (33.7% of holdings) with no purchases in the last 6 months.
Institutional Movements: Mixed sentiment with 185 institutions increasing positions and 167 decreasing.
Earnings Report: Scheduled for release after the market close on Wednesday, which could cause volatility.

ETF Analysis:

Avantis US Large Cap Equity ETF (AVLC): Implied upside of 21.88% for the ETF, with CORT showing a potential upside of 73.21% based on analyst targets.

Conclusion:

Based on the analysis, the stock price of CORT is predicted to be $58.50 for the next trading week. The recommendation is to sell due to bearish technical indicators and insider selling activity. However, the upcoming earnings report could impact this outlook positively if results exceed expectations.

Analysis and Insights

To predict the stock price of Corcept Therapeutics (CORT) for the next trading week, we analyze both technical indicators and recent news sentiment.

Technical Analysis:

RSI (14): 48.95 (neutral, not oversold or overbought)
MACD: -1.41 (bearish signal line crossover)
Fibonacci Levels: Pivot at 56.43, resistance at 59.02, and support at 53.85

News Sentiment:

Insider Activity: Significant insider selling (33.7% of holdings) with no purchases in the last 6 months.
Institutional Movements: Mixed sentiment with 185 institutions increasing positions and 167 decreasing.
Earnings Report: Scheduled for release after the market close on Wednesday, which could cause volatility.

ETF Analysis:

Avantis US Large Cap Equity ETF (AVLC): Implied upside of 21.88% for the ETF, with CORT showing a potential upside of 73.21% based on analyst targets.

Conclusion:

COR Similar Chart Price Prediction

The price of COR is predicted to go up -5.65%, based on the high correlation periods with SPB. The similarity of these two price pattern on the periods is 98.37%.

COR

Future prediction

Down: -5.65%

SPB

Down: -5.65%Similarity: 98.37%

COR Revenue Forecast

COR EPS Forecast

COR FAQs

What is COR revenue forecast for next quarter？

The market consensus for COR's revenue in the upcoming quarter is projected to be approximately $81.255B USD.

What is COR eps forecast for next quarter？

COR VS S&P500

Cencora Inc

SPDR S&P 500

Cencora distributes pharmaceutical products to nearly one third of the industry, leading to substantial negotiation leverage with generic drug manufacturers.

A robust demand for GLP-1s (diabetes drug) provides a strong tailwind to Cencora's top line and allows the distributor to offer other high-margin services to both manufacturers and customers.

Technology advancements continue to improve Cencora's performance and present new opportunities for wholesalers.

Ask Intellectia about COR

COR Analyst's Forecast

Stephen Baxter

Wells Fargo

Hold

2025-03-14

Price Target

$251 → $274

Upside

+6.17%

Wells Fargo raised the firm's price target on Cencora to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora's results and more recent guidance raise. Estimates for all years move higher based on U.S. strength, partially offset by lower International vs. Wells' previous model.